In a report released today, Kevin DeGeeter from Oppenheimer assigned a Buy rating to 9 Meters Biopharma (NMTR – Research Report), with a price target of $5.50. The company’s shares closed last Monday at $1.07.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 38.5% and a 45.5% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Sensei Biotherapeutics, and Cellectar Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 9 Meters Biopharma with a $4.13 average price target, a 282.4% upside from current levels. In a report issued on July 8, BMO Capital also assigned a Buy rating to the stock with a $5.00 price target.
Based on 9 Meters Biopharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.43 million. In comparison, last year the company had a GAAP net loss of $3.6 million.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Innovate Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It foucs on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.